scispace - formally typeset
J

Jufang Shan

Researcher at St. Jude Children's Research Hospital

Publications -  9
Citations -  870

Jufang Shan is an academic researcher from St. Jude Children's Research Hospital. The author has contributed to research in topics: Wnt signaling pathway & PDZ domain. The author has an hindex of 8, co-authored 9 publications receiving 808 citations. Previous affiliations of Jufang Shan include University of Tennessee Health Science Center.

Papers
More filters
Journal ArticleDOI

An Antagonist of Dishevelled Protein-Protein Interaction Suppresses β-Catenin–Dependent Tumor Cell Growth

TL;DR: FJ9 is among the first non-peptide inhibitors to show therapeutic efficacy through disruption of PDZ protein-protein interactions, down-regulating canonical Wnt signaling and suppressing tumor cell growth.
Journal ArticleDOI

Identification of a specific inhibitor of the Dishevelled PDZ domain

TL;DR: This compound provides a basis for rational design of high-affinity inhibitors of the PDZ domain, which can block Wnt signaling by interrupting the Fz-Dvl interaction.
Journal ArticleDOI

Discovery and Characterization of a Small Molecule Inhibitor of the PDZ Domain of Dishevelled

TL;DR: The biological effects suggest that by blocking the PDZ domain of Dvl, the compound identified in the studies effectively inhibits the Wnt signaling and thus provides a useful tool for studies dissecting the WNT signaling pathways.
Journal ArticleDOI

Structural insight into the mechanisms of Wnt signaling antagonism by Dkk.

TL;DR: The structure of the Dkk functional domain was examined and its interactions with low density lipoprotein receptor-related protein (LRP) 5/6 were elucidated and it was shown that the ligand binding site of the third LRP5/6 β-propeller domain matches DKK2C best, suggesting that this domain binds to Dkk2C with higher affinity.
Journal ArticleDOI

Chemical and genetic evidence for the involvement of Wnt antagonist Dickkopf2 in regulation of glucose metabolism

TL;DR: It is suggested that DKK2 may be a potential therapeutic target for treating type 2 diabetes by identifying small-molecule inhibitors of Wnt antagonist Dkk through molecular modeling, computation-based virtual screens, and biological assays.